Exelon 4 6mg Patch 5 30s

What it is used for: Alzheimer.

Indications as listed by the manufacturer: Rivastigmine transdermal system contains rivastigimine, an acetylcholinesterase inhibitor indicated for the: - Treatment of mild to moderate dementia of the Alzheimer’s type - Treatment of mild to moderate dementia associated with Parkinson’s disease

How it works: Pathological changes in dementia such as Alzheimerâs Disease involve cholinergic neuronal pathways that project from the basal forebrain to the cerebral cortex and hippocampus. These pathways are known to be involved in attention, learning and memory and other cognitive processes. Rivastigmine, a brain-selective acetyl- and butyryl-cholinesterase inhibitor of the carbamate type, is thought to facilitate cholinergic neurotransmission by slowing the degradation of acetylcholine released by functionally intact cholinergic neurons. Data from animal studies indicate that rivastigmine selectively increases the availability of acetylcholine in the cortex and hippocampus. Thus, Exelon may have an ameliorative effect on cholinergicmediated cognitive deficits associated with Alzheimerâs Disease and with Parkinsonâs disease. In addition, there is some evidence that cholinesterase inhibition could slow the formation of amyloidogenic beta-amyloid-precursor protein (APP) fragments, and thus of amyloid plaques, which are one of the main pathological features of Alzheimerâ

Active ingredient: Rivastigmine.

Reported side effects: Blood and Lymphatic System Disorders: Frequent: Anemia ; Cardiac Disorders: Infrequent: Angina pectoris, cardiac failure, bradycardia, atrial fibrillation, supraventricular extrasystoles, myocardial infarction, tachycardia, arrhythmia, atrioventricular block ; Ear and Labyrinth Disorders: Infrequent: Tinnitus. Eye Disorders: Infrequent: Cataract, glaucoma, vision blurred ; Gastrointestinal System: Frequent: Constipation, gastritis. Infrequent: Gastroesophageal reflux disease, hematochezia, peptic ulcer, hematemesis, pancreatitis, salivary hypersecretion ; General Disorders and Administration Site Conditions: Infrequent: Application site dermatitis, application site irritation, peripheral edema, chest pain, application site eczema, hyperpyrexia ; Hepatobiliary Disorders: Infrequent: Cholecystitis. Infections and Infestations: Frequent: Nasopharyngitis, pneumonia. Infrequent: Diverticulitis ; Injury, Poisoning and Procedural Complications: Frequent: Fall. Infrequent: Hip fracture, subdural hematoma .

Known drug interactions: Rivastigmine transdermal system should not be given together with other medicines with similar effects (cholinomimetic agents) or with anticholinergic medicines.

Initial Dose: Treatment is started with the rivastigmine transdermal system Patch 4.6 mg/24 hours. After a minimum of four weeks of treatment and if well tolerated, this dose should be increased to rivastigmine transdermal system Patch 9.5 mg/24 hours, which is the recommended effective dose. Maintenance Dose: Dose increases should occur only after a minimum of 4 weeks at the previous dose, and only if the previous dose has been well tolerated. The maximum recommended dose is 9.5 mg/ 24 hours. OR As directed by your physician.

Active ingredient: Rivastigmine. Labelled strength: 4.6MG.

Store this medicine at room temperature, away from direct light and heat.

Manufactured by Exelon Laboratories (Pvt) Ltd.. Country of origin: India.